- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Urine Test to Predict Recurrence of Bladder Cancer
A DNA methylation marker test performed on urine samples obtained from patients with non-muscle-invasive bladder cancer (NMIBC) has the ability to predict tumor recurrence with both high sensitivity and specificity.
A DNA methylation marker test performed on urine samples obtained from patients with non-muscle-invasive bladder cancer (NMIBC) has the ability to predict tumor recurrence with both high sensitivity and specificity.
The urine test, which measures three distinct DNA methylation markers, detected tumor recurrence with both high sensitivity and specificity (80% sensitivity and 97% specificity) in NMIBC patients.
While standard methods of monitoring which include cytology and cystoscopy were able to detect tumor recurrence in only 35 percent and 15 percent of these patients respectively, the new marker test performed well and predicted tumor recurrence in 80 percent of the patients who had a recurrence.The research
was published online April 1 in
, a journal of the American Association for Cancer Research.
Read the original report here:
Source: Forbes
Clinical Cancer Research
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
